13/05/2026 – AB Science reports its revenues for the year 2025 and provides an update on its activities Download PDF Post navigationPreviousPrevious post:AB Science announces the successful completion of a EUR 3.2 million private placementRelated PostsAB Science announces the successful completion of a EUR 3.2 million private placement29 April 2026AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors27 April 2026New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients20 April 2026Update on clinical development program16 April 2026AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS24 February 2026FDA granted the status of Minor Use in Major Species (MUMS) for Masivet®9 February 2026
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors27 April 2026
New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients20 April 2026
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS24 February 2026
